COL4A5 and Buschke-Ollendorff syndrome: However, it is the first study to investigate serum concentrations of COL4A5 in BOS patients at and before clinical diagnosis of BOS, and to propose COL4A5 as a potential predictive biomarker of BOS development and as a marker of negative prognosis in lung transplant patients.